Overview
- Anthropic disclosed Tuesday that Claude ran a roughly 64‑hour design campaign and produced 318,484 de novo minibinder sequences across 553,052 design‑toxin pairings.
- Researchers selected 211 candidate designs for experimental follow‑up and sent them to Adaptyv Bio and Twist Bioscience for cell‑free and mammalian Fc‑fusion expression and surface plasmon resonance binding assays.
- Seventeen of the 211 tested designs met Anthropic’s predefined binding criteria in the lab, with the strongest candidates showing tight affinity in duplicate measurements.
- The study measured binding only and did not test whether any candidates neutralize toxins in cells or animals, and Anthropic explicitly said it is not claiming to have produced an antivenom.
- Anthropic framed the work as an early, supervised research demonstration that could speed hypothesis generation in early discovery, said the capabilities are not broadly available, and plans to publish the 211 designs and experimental data for independent review.